Accelerating Drug Validation with Quantitative Imaging
Quantitative preclinical molecular imaging services that accelerate drug validation, providing the evidence needed to de-risk drug development.
Quantitative Preclinical Imaging
Three critical questions, answered in vivo.
Customized preclinical imaging studies for a comprehensive characterization of your drug candidate.
Quantitative Molecular Imaging
TheraPET4D® automates whole-body quantification of drug delivery, target binding and washout kinetics, providing comprehensive quantitative and accurate insights for novel biological therapeutics.
Validate your candidates. Select your lead.
Compare drug candidates to identify the best lead while reducing development time and costs.
Labeling
Your therapeutic candidate is labeled using methods that preserve its biological properties and behavior, ensuring representative in vivo performance.
In vivo imaging
Longitudinal whole-body PET imaging captures the in vivo distribution and behavior of your therapeutic over time.
Image analysis & Quantification
TheraPET4D® converts imaging data into quantitative biodistribution and pharmacokinetic profiles, enabling accurate estimation of drug delivery, target engagement and clearance across tissues of interest.
Data package
A comprehensive report providing the quantitative evidence needed to support confident go/no-go decisions before clinical development.
World-class molecular imaging infrastructure.
MIBIOTRACE provides access to an integrated preclinical imaging ecosystem, combining radiochemistry, multimodal imaging and quantitative analysis within a single workflow.
- Radiopharmacy laboratory
- Labeling procedures
- Image acquisition
- PET · PET/CT · PET/MRI · SPECT/CT
- Animal facilities
- Direct access to animal models
Meet the team behind the company.
Validate your candidate.
Book a technical consultation to explore how quantitative molecular imaging can accelerate your drug development.